UPDATE: Credit Suisse Upgrades Sequenom to Neutral on Lessened Risks

In a report published Monday, Credit Suisse analyst Vamil Divan upgraded the rating on Sequenom (NASDAQ: SQNM ) from Underperform to Neutral, and slightly raised the price target from $4.00 to $4.50. In the report, Divan noted, “Following daily moves in SQNM's stock can get one dizzy, but after seven